Osteoporosis Screening Guidelines

Key Screening Recommendations

The American College of Physicians recommends that all women aged 65 years and older should undergo routine screening with DXA of the hip and lumbar spine, regardless of risk factors 1, 2
Postmenopausal women younger than 65 years should be screened if their fracture risk equals or exceeds that of a 65-year-old white woman without additional risk factors 1, 2
The US Preventive Services Task Force found insufficient evidence to recommend for or against routine screening in men, though some specialty societies recommend screening at age 70 or older 1, 3

Screening should continue as long as the patient is a candidate for treatment and has sufficient life expectancy to benefit from fracture prevention, according to the American College of Physicians 1
Hip fractures carry a significant one-year mortality risk, making prevention valuable even in older adults 4
More than one-third of men who experience hip fractures die within one year 4, 5

For patients with normal bone density, repeat screening every 2-3 years, as recommended by the American College of Physicians 6
Women with normal BMD at age 65 may not transition to osteoporosis for almost 17 years, suggesting less frequent screening in this group 6
Patients with osteopenia may need screening every 4-8 years unless baseline T-score is below -2.0 6

Patient has limited life expectancy (generally less than 5-10 years) where fracture prevention would not meaningfully impact quality of life, according to the American College of Physicians 1
Patient would not be a candidate for osteoporosis treatment due to contraindications, severe comorbidities, or patient preference 1
Patient has severe functional limitations where the burden of screening and treatment outweighs potential benefits 1

Do not arbitrarily stop screening at a specific age without considering individual factors, as recommended by the American College of Physicians 1
Avoid repeating DXA scans more frequently than every 2 years in patients with normal BMD, as this provides no clinical benefit and exposes patients to unnecessary radiation 6
Do not overlook that fracture risk increases with age, making screening potentially more valuable in older adults who remain treatment candidates 4, 5

The USPSTF guidelines do not establish a specific upper age limit for discontinuing osteoporosis screening, as stated in the 2025 guidelines 7
The 2002 USPSTF statement acknowledged that there are no data to determine the appropriate age to stop screening and few data on osteoporosis treatment in women older than 85 years of age, according to the US Preventive Services Task Force 8

The United States Preventive Services Task Force (USPSTF) recommends routine bone density screening with DXA for all women aged ≥ 65 years and does not set an upper age limit for stopping screening, emphasizing that decisions should be individualized based on treatment candidacy and life expectancy rather than chronological age alone. 9

Clinical evidence indicates that the therapeutic benefits of osteoporosis medications (e.g., bisphosphonates, denosumab) typically become apparent 18–24 months after treatment initiation, a factor that should be considered when evaluating whether a patient’s expected remaining lifespan is sufficient to realize fracture‑prevention advantages. 10